Tompkins Financial Corp Reduces Holdings in Bristol-Myers Squibb (NYSE:BMY)

Tompkins Financial Corp lessened its holdings in Bristol-Myers Squibb (NYSE:BMY) by 10.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 9,086 shares of the biopharmaceutical company’s stock after selling 1,057 shares during the period. Tompkins Financial Corp’s holdings in Bristol-Myers Squibb were worth $470,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of BMY. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its position in Bristol-Myers Squibb by 4.7% during the 1st quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 14,492 shares of the biopharmaceutical company’s stock worth $786,000 after purchasing an additional 654 shares in the last quarter. TCI Wealth Advisors Inc. lifted its position in Bristol-Myers Squibb by 6.2% during the first quarter. TCI Wealth Advisors Inc. now owns 6,882 shares of the biopharmaceutical company’s stock valued at $373,000 after buying an additional 402 shares in the last quarter. Montag A & Associates Inc. grew its stake in Bristol-Myers Squibb by 9.1% during the first quarter. Montag A & Associates Inc. now owns 20,999 shares of the biopharmaceutical company’s stock worth $1,139,000 after buying an additional 1,758 shares during the period. Keudell Morrison Wealth Management increased its position in shares of Bristol-Myers Squibb by 50.4% in the first quarter. Keudell Morrison Wealth Management now owns 16,452 shares of the biopharmaceutical company’s stock worth $892,000 after acquiring an additional 5,511 shares in the last quarter. Finally, Atomi Financial Group Inc. purchased a new position in shares of Bristol-Myers Squibb in the 1st quarter valued at $231,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol-Myers Squibb Stock Performance

Shares of BMY stock traded down $0.57 during trading hours on Friday, reaching $54.14. The stock had a trading volume of 9,218,631 shares, compared to its average volume of 14,395,481. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09. The firm has a 50-day simple moving average of $51.87 and a 200-day simple moving average of $46.81. The firm has a market capitalization of $109.81 billion, a PE ratio of -15.09, a price-to-earnings-growth ratio of 12.39 and a beta of 0.44. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $56.80.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.31. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The company had revenue of $11.89 billion for the quarter, compared to analysts’ expectations of $11.26 billion. During the same quarter in the previous year, the company posted $2.00 earnings per share. The business’s revenue for the quarter was up 8.4% compared to the same quarter last year. As a group, equities analysts forecast that Bristol-Myers Squibb will post 0.9 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Friday, October 4th were paid a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.43%. The ex-dividend date of this dividend was Friday, October 4th. Bristol-Myers Squibb’s dividend payout ratio is currently -66.85%.

Analyst Ratings Changes

A number of research analysts have commented on BMY shares. Deutsche Bank Aktiengesellschaft reduced their price objective on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a research note on Tuesday, July 23rd. TD Cowen lifted their price target on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. Citigroup cut Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their price target for the stock from $75.00 to $55.00 in a research note on Friday, October 25th. BMO Capital Markets raised their price objective on shares of Bristol-Myers Squibb from $53.00 to $57.00 and gave the stock a “market perform” rating in a report on Friday, November 1st. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $50.00 target price on shares of Bristol-Myers Squibb in a report on Friday, October 18th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $53.00.

Insider Buying and Selling

In related news, EVP Samit Hirawat bought 1,830 shares of the stock in a transaction on Friday, November 1st. The shares were purchased at an average price of $54.67 per share, with a total value of $100,046.10. Following the purchase, the executive vice president now owns 62,109 shares in the company, valued at approximately $3,395,499.03. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, SVP Phil M. Holzer sold 700 shares of Bristol-Myers Squibb stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $55.62, for a total transaction of $38,934.00. Following the transaction, the senior vice president now directly owns 11,760 shares of the company’s stock, valued at $654,091.20. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Samit Hirawat purchased 1,830 shares of the business’s stock in a transaction on Friday, November 1st. The stock was acquired at an average cost of $54.67 per share, with a total value of $100,046.10. Following the completion of the acquisition, the executive vice president now directly owns 62,109 shares in the company, valued at $3,395,499.03. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.